X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Pharma: The regulatory angle... - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Oct 9, 2007

    Pharma: The regulatory angle...

    Healthcare has assumed significant importance the world over and the fact that the developed nations of the world spend around 8% to 14% of the GDP on healthcare further highlights the importance of the same. Moreover, the issue of drug pricing has become a debatable point between the government and the pharmaceutical industry with the former looking to keep the costs under control in a bid to make medicines more affordable to the larger sections of the society. In this article, we shall take a look at some of the regulatory acts, which have had an important bearing on the fortunes of the Indian pharma industry and the outlook going forward.

    The Hatch Waxman Act: In 1984, the US government introduced the Hatch-Waxman Act to encourage generic versions of patent protected drugs. The rationale behind the same was to maintain inducements necessary for brand name companies to research and develop new drugs and at the same time enable lower cost generic products to reach the market. This act has been a boon for generic companies worldwide including Indian players enabling them to bolster their revenue streams by launching generic drugs in the US market. The fact that healthcare accounts for nearly 14% of US' GDP and the mounting pressure on the government to reduce the healthcare costs has further provided an impetus to generic companies focusing on this region. Another important provision of the Hatch-Waxman Act was the grant of the 180-day exclusivity period for a generic company successful in challenging the patent of a drug of the innovator.

    That said, with their R&D pipelines showing signs of drying up, global innovator companies are looking to fiercely protect revenues of their blockbuster drugs and have introduced authorised generics which reduce the extent of revenues and profitability that the challenging generic company can earn during he exclusivity period. Besides on an overall basis, the pricing pressure has continued unabated in the US due to rising competition and this price erosion has become fierce for new molecules losing patent expiry.

    Product patent law: The product patent law is an important and fundamental change that has taken place for the Indian pharmaceutical industry. Besides putting an end to the reverse engineering practices, from a strategic point of view, this law is important, as it is expected to increase India's relevance in the global pharmaceutical industry in terms of launching patented molecules and in terms of being a preferred destination for contract research and manufacturing. Also, it is expected to increase the pace of product launches by MNC companies in India. However, we believe that resolving issues relating to data exclusivity, definition of patentability and scope of compulsory licensing by the government will be critical going forward. We do not expect a free hand for such patented products and believe that the pricing of the same is most likely to be subject to negotiation.

    For domestic companies, over a longer term, the increased likelihood of a slowdown in the pace of product launches has prompted many of them to intensify their focus on

    • The global generics market

    • R&D - in a bid to launch their own proprietary molecules and

    • In-licensing by leveraging their marketing and distribution network to launch the products of global innovators in the domestic market.

    Drug Pricing Control Order: The prices of drugs in India have been one of the lowest in the world, not only due to the fragmented nature of the industry and consequently increased competition, but also the price control imposed by the National Pharmaceutical Pricing Authority (NPPA). But this has failed to translate into better healthcare service to the larger section of the Indian populace over the last decade.

    The price control on drugs has always been a bone of contention between the government and the Indian pharma industry. In 1970, almost all bulk drugs and their formulations were under price control. This number got reduced to 347 bulk drugs in 1979, 142 in 1987 and finally to 74 in 1995. While the National Pharmaceutical Policy 2002 had been contemplating reducing the span of drugs under price control further, this has been mired in controversy and is currently under litigation. The New Pharmaceutical Policy 2006, which is yet to be passed by the government proposes to bring 354 drugs on the National List of Essential Medicines under price control and has been stiffly opposed by the pharmaceutical industry.

    To conclude...
    The abov ementioned regulatory acts have been amongst the more significant ones having an important bearing on the fortunes of the Indian pharmaceutical industry. Besides this, with domestic pharma companies making increasing strides in the global generics market, the challenges posed by regulatory changes and healthcare reforms in various countries are also expected to play a role in determining the performance of these companies going forward. Thus, while having a widespread geographical reach is one way of de-risking revenues, efficiencies at the operating level and continuous launch of products are equally critical to have that upper edge for pharma companies going forward.

     

     

    Equitymaster requests your view! Post a comment on "Pharma: The regulatory angle...". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    The Power of 5 Minutes (The 5 Minute Wrapup)

    Jun 16, 2017

    Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

    Aug 8, 2017

    'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    S&P BSE HEALTHCARE


    Aug 21, 2017 (Close)

    S&P BSE HEALTHCARE 5-YR ANALYSIS

    COMPARE COMPANY

    MARKET STATS